Retatrutide half life is one of the most searched technical questions about Eli Lilly’s experimental triple agonist, and for good reason: the amount of time a drug remains in circulation helps determine how often it may need to be administered.
Retatrutide has a reported half-life of approximately six days in humans, supporting its once-weekly injection schedule.
On November 2, Hong Kong-listed Ascletis Pharma announced that it would present a poster at ObesityWeek 2026 describing its own triple-agonist peptide, ASC37, as having a sixfold longer half-life than retatrutide in non-human primates.
The company is developing ASC37 for potentially once-monthly to once-quarterly dosing. If that approach eventually works in people, it could offer a different treatment schedule from the weekly injections that dominate the current obesity market.
But there are important qualifications.
The sixfold comparison comes from animals. Ascletis used a proprietary slow-release depot formulation for ASC37 and a conventional liquid formulation for retatrutide. And the company’s earlier January announcement described the difference as approximately sevenfold, not sixfold.
The result deserves attention. It also deserves a careful reading of what was actually measured.
What Retatrutide Half Life Actually Means
Retatrutide, originally known as LY3437943, is a peptide that activates three metabolic hormone receptors: GLP-1, GIP and glucagon.
Those three pathways influence overlapping aspects of appetite, glucose regulation and energy metabolism. Lilly is studying whether combining them in one molecule can produce stronger clinical effects than existing obesity treatments.
In a Phase 1b study published in The Lancet in 2022, Shweta Urva and colleagues investigated retatrutide in 72 adults with type 2 diabetes.
The study evaluated repeated doses over 12 weeks, including pharmacokinetics, safety, tolerability and metabolic effects.
Retatrutide has a reported human pharmacokinetic half-life of approximately six days, a characteristic consistent with once-weekly administration.
Pharmacokinetic half-life describes how long it takes for the relevant drug concentration to decrease by half during a defined phase of its concentration-time profile.
It does not, by itself, tell researchers how much weight a person will lose or exactly how long meaningful receptor activity will remain after an injection.
A dosing schedule also depends on how much drug is absorbed, the relationship between concentration and clinical effect, safety margins and the tolerability of repeated treatment.
Retatrutide’s development program has now advanced into Phase 3, generating substantial human weight-loss data. But the established six-day pharmacokinetic estimate remains distinct from the results Ascletis is reporting for ASC37 in monkeys.
That difference in evidence matters more than the apparent simplicity of a sixfold comparison.
Ascletis Said Sevenfold in January. The November Poster Says Sixfold.
ASC37 is an investigational GLP-1R/GIPR/GCGR triple-agonist peptide developed by Ascletis.
It targets the same three receptor systems as retatrutide, but it is a different molecule with a different development strategy.
Ascletis selected ASC37 as a clinical development candidate in January 2026 and described it as a potential once-monthly subcutaneous treatment.
In its January 20 announcement, the company reported that proprietary ASC37 depot formulations had an average observed half-life of approximately 17 days in head-to-head non-human primate studies.
Retatrutide, tested in a standard liquid formulation in the same animal comparison, had a reported observed half-life of approximately 2.5 days.
That produced the company’s approximately sevenfold headline.
Ascletis also reported that ASC37 showed approximately fivefold greater activity at the GLP-1 receptor and fourfold greater activity at the GIP and glucagon receptors in laboratory assays.
Those are in-vitro potency findings, not proof of greater clinical weight loss or better safety in patients.
On November 2, the company announced a poster titled “ASC37 Showed 6-Fold Longer Half-Life Than Retatrutide in NHP and Marked Weight Loss in DIO Mice.”
The poster is scheduled for November 14 at ObesityWeek, held at the Gaylord National Resort & Convention Center in National Harbor, Maryland.
The shift from approximately sevenfold to sixfold is worth noting. Different analyses, formulations or rounding conventions could potentially explain it, but the November announcement does not provide enough underlying data to establish why the reported multiplier changed.
Neither multiplier is a demonstrated advantage in human patients.
The disclosed comparison remains preclinical, and the full poster dataset was not included in the November 2 announcement.
Why the Comparison Isn’t Like-for-Like
The most important detail is hidden in the formulation language.
ASC37 was tested using Ascletis’ proprietary slow-release subcutaneous depot system. Retatrutide was tested in a conventional liquid formulation.
A depot formulation is designed to release medication gradually from the injection site, potentially extending the observed concentration-time profile.
Ascletis calls its formulation technology the Ultra-Long-Acting Platform, or ULAP. The company describes the system as allowing engineers to adjust release rates and potentially reduce fluctuations between peak and trough drug concentrations.
That is a legitimate area of pharmaceutical research.
But comparing a depot formulation against a standard liquid solution does not isolate the inherent pharmacological properties of the two peptide molecules.
Part of the observed difference may arise from the formulation, part from the molecule, or from both acting together.
There is another technical qualification.
In its January announcement, Ascletis described the observed half-life using time to 50% of maximum concentration, or Cmax.
That is not necessarily equivalent to the terminal elimination half-life conventionally reported in human pharmacokinetic studies.
The difference matters when a slow-release formulation continues delivering drug into circulation over an extended period.
The shape of the blood-concentration curve can reflect ongoing absorption from the injection site as well as removal of the drug from the body.
It would therefore be misleading to compare ASC37’s approximately 17-day observed value in monkeys directly against retatrutide’s six-day half-life in humans and describe the resulting ratio as a clinical advantage.
The sevenfold figure reported in January came from Ascletis’ own animal comparison against a roughly 2.5-day retatrutide value in that experiment.
The conclusion is specific: Ascletis reported substantially longer observed exposure for its ASC37 depot formulation in non-human primates.
Whether that result translates into a useful monthly or quarterly schedule in people remains unknown.
A depot against a liquid formulation tests a delivery system as well as a molecule.
What the Mouse Studies Actually Showed
The November poster announcement refers to marked weight loss in diet-induced obese mice, but Ascletis had already published related preclinical figures in July.
On July 27, the company announced results from an 11-day experiment comparing ASC37 against tirzepatide in diet-induced obese mice.
Both treatments were administered by daily subcutaneous injection in the reported comparison.
At a matched dose of 1 nanomole per kilogram, Ascletis reported mean body-weight reductions of 14.1% with ASC37 and 7.5% with tirzepatide.
The company described this as 88% greater relative weight reduction with ASC37 and reported a p-value of 0.0279.
At higher experimental doses of ASC37, the same release reported weight reductions of 30.1% and 41.5% in the mouse model.
Those are unusually large changes over a short period and require careful interpretation within the animal model, dose levels and experimental conditions.
They do not establish that ASC37 would cause comparable weight loss in humans.
The comparator also matters. The July efficacy experiment compared ASC37 with tirzepatide, not retatrutide.
And the injections were administered daily for the experiment. The findings therefore do not demonstrate that one monthly ASC37 injection produces sustained weight loss.
That is a separate hypothesis involving the drug’s slow-release formulation, long-term exposure and pharmacodynamic effects.
The November 14 poster may add more details about the preclinical work. Until the complete presentation is available, however, its abstract title should not be treated as a substitute for the underlying study design and results.
Mouse efficacy and monkey pharmacokinetics are useful early screening tools. They are not interchangeable with a clinical trial.
The Road From Animal Data to a Monthly Injection
Ascletis’ development timeline also deserves a careful reading.
When the company selected ASC37 as a clinical candidate in January 2026, it said it expected to submit an investigational new drug application to the US Food and Drug Administration in the second quarter of the year.
It also anticipated starting Phase 1 research in the second half of 2026.
By July, the stated IND submission target had shifted to the third quarter of 2026. Ascletis also described plans for both injectable and oral ASC37 formulations.
The November 2 announcement focuses on preclinical poster presentations and does not establish that a human ASC37 trial has begun or that clinical pharmacokinetic results are available.
That is an important limitation. An announced filing target is not confirmation that an IND was submitted, cleared or followed by first-in-human dosing.
For the long-acting injectable, the initial clinical questions will involve drug exposure, tolerability and whether the proposed release profile behaves predictably in people.
Human pharmacokinetic measurements would help establish whether the prolonged animal exposure translates across species.
Then researchers would need to test whether an extended dosing interval maintains enough receptor activity to produce meaningful weight loss.
Longer persistence also creates a potential trade-off.
GLP-1-related medicines commonly produce gastrointestinal adverse effects, including nausea and vomiting. A formulation that releases drug over weeks may be less flexible if exposure needs to be reduced after an adverse reaction.
That is a pharmacological concern to investigate, not evidence that ASC37 has already demonstrated an unusually difficult safety profile.
Ascletis is also considering ASC37 in combination with ASC36, its investigational long-acting amylin receptor agonist, and has described possible development for other metabolic conditions including MASH.
These are development ambitions. Each new indication, formulation and combination adds questions that clinical studies must answer.
The Race for Fewer Injections Is Getting Crowded
Ascletis is entering a field in which drug developers increasingly compete on more than maximum weight loss.
Semaglutide and tirzepatide have established weekly treatment as a familiar option for many patients using injectable obesity medicines.
Retatrutide is advancing through a broad Phase 3 program, generating human evidence on the potential of triple receptor agonism.
Meanwhile, other developers are investigating monthly injections, less-frequent maintenance schedules and oral alternatives.
AbbVie, for example, is investigating ABBV-295, a long-acting amylin analogue with early clinical pharmacokinetic data suggesting the possibility of extended dosing intervals.
We examined its dosing hypothesis and the limits of the early evidence in our report on AbbVie’s monthly amylin injection program.
Viking Therapeutics is also investigating reduced injection frequency for weight maintenance with its dual GLP-1/GIP agonist VK2735.
Ascletis’ proposed advantage is distinct: a triple-agonist peptide combined with an engineered release system intended to support longer dosing intervals.
But convenience cannot be evaluated from a concentration curve alone.
A monthly injection would need to preserve clinically meaningful weight-loss efficacy, maintain acceptable safety and offer a practical advantage over treatments already available or further along in development.
As we explained in our examination of retatrutide’s triple-agonist biology, activating more receptors is not automatically sufficient to make a better medicine.
The balance of receptor activity, the treatment schedule and the safety profile all matter.
There is another complication for the research-peptide market.
Retatrutide is frequently marketed online as a research chemical despite remaining an investigational drug without FDA approval.
Published clinical pharmacokinetic data for retatrutide do not establish the identity, purity or safety of unregulated products sold under the same name.
ASC37 is also investigational. Its company-reported preclinical findings do not support consumer use or establish a human dosing schedule.
The next obesity-drug competition may increasingly involve the calendar as well as the scale.
But three milestones would materially change ASC37’s evidence profile: human pharmacokinetic data showing reliably extended exposure, a tolerability profile appropriate for prolonged drug release, and clinically meaningful weight loss sustained across an established dosing interval.
None of those human findings is established by the November 2 announcement.
The forthcoming ObesityWeek poster is therefore a preclinical milestone, not proof of a new monthly obesity treatment.
Ascletis has shown a potentially interesting formulation strategy. It has not yet shown that the same approach will outperform retatrutide in people.
Sixfold in a monkey study may be enough to earn attention. It is not enough to decide the next generation of obesity treatment.
Disclosure: Grey Pepper’s owner also has business interests in the research-peptide market.
Sources
Primary November announcement: Ascletis Pharma — ASC37 and ASC48 Poster Presentations at ObesityWeek 2026. November 2, 2026.
Original development announcement: Ascletis Pharma — ASC37 Selected as a Clinical Development Candidate. January 20, 2026.
Mouse efficacy and updated development plans: Ascletis Pharma via BioSpace — ASC37 Diet-Induced Obese Mouse Study. July 27, 2026.
Retatrutide clinical research: Urva S et al. LY3437943, a Novel Triple GIP, GLP-1, and Glucagon Receptor Agonist in People With Type 2 Diabetes. The Lancet. Published online October 27, 2022. DOI: 10.1016/S0140-6736(22)02033-5.
Clinical pharmacology background: Retatrutide — A Game Changer in Obesity Pharmacotherapy. Review of retatrutide pharmacology and clinical findings.
